-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, March 26.
Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for listing.
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 2 billion yuan.
Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for listing.
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 2 billion yuan.
Escitalopram is the single-S-enantiomer of citalopram, a bicyclic hydrogenated phthalide derivative, and is clinically used to treat depression, panic disorder with or without agoraphobia.
According to data from Meinenet, the total sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 exceeded 20 100 million yuan, the growth rate has declined in the first half of 2020.
Consistency evaluation and application status of escitalopram oxalate tablets (including new classification for production)
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, 5 companies have submitted supplementary applications for the consistency evaluation of escitalopram oxalate tablets.
Among them, the products of Jilin Province West Point Pharmaceutical, Sichuan Kelun Pharmaceutical, Shandong Tokyo Medical Pharmaceutical, and Hunan Dongting Pharmaceutical have successfully passed the evaluation; 4 The company submitted the product listing application under the new registration classification, and the products created by Zhejiang Huahai Pharmaceutical, Fuan Pharmaceutical, Ningbo Tianheng Pharmaceutical/Fujian Haixi New Drug have been approved for production and deemed to have been reviewed.
Among them, the products of Jilin Province West Point Pharmaceutical, Sichuan Kelun Pharmaceutical, Shandong Tokyo Medical Pharmaceutical, and Hunan Dongting Pharmaceutical have successfully passed the evaluation; 4 The company submitted the product listing application under the new registration classification, and the products created by Zhejiang Huahai Pharmaceutical, Fuan Pharmaceutical, Ningbo Tianheng Pharmaceutical/Fujian Haixi New Drug have been approved for production and deemed to have been reviewed.
From 2021 to the present, Dongyang Pharmaceutical has been approved for marketing
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, since 2021, Dongyang Pharmaceutical has been approved for marketing of 4 generic drugs, among which Entacapone tablets are the first imitation, and duloxetine hydrochloride enteric-coated capsules are the company’s first antidepressant imitations approved for marketing.
Pharmaceutical.
com, since 2021, Dongyang Pharmaceutical has been approved for marketing of 4 generic drugs, among which Entacapone tablets are the first imitation, and duloxetine hydrochloride enteric-coated capsules are the company’s first antidepressant imitations approved for marketing.
Pharmaceutical.
New antidepressant drug being developed by Dongyang Sun Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of new antidepressant drugs, the domestic class 1 new drug HEC113995PA·H2O tablets are in phase I clinical trials, and the 2.
2 class improved new drug vilazodone hydrochloride tablets have been applied for clinical trials and are currently under review and approval.
2 class improved new drug vilazodone hydrochloride tablets have been applied for clinical trials and are currently under review and approval.
Source: Minet database
Note: The statistics are as of March 25.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Medical News, March 26.
Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for listing.
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 2 billion yuan.
Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for listing.
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 2 billion yuan.
Escitalopram is the single-S-enantiomer of citalopram, a bicyclic hydrogenated phthalide derivative, and is clinically used to treat depression, panic disorder with or without agoraphobia.
According to data from Meinenet, the total sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 exceeded 20 100 million yuan, the growth rate has declined in the first half of 2020.
Consistency evaluation and application status of escitalopram oxalate tablets (including new classification for production)
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, 5 companies have submitted supplementary applications for the consistency evaluation of escitalopram oxalate tablets.
Among them, the products of Jilin Province West Point Pharmaceutical, Sichuan Kelun Pharmaceutical, Shandong Tokyo Medical Pharmaceutical, and Hunan Dongting Pharmaceutical have successfully passed the evaluation; 4 The company submitted the product listing application under the new registration classification, and the products created by Zhejiang Huahai Pharmaceutical, Fuan Pharmaceutical, Ningbo Tianheng Pharmaceutical/Fujian Haixi New Drug have been approved for production and deemed to have been reviewed.
Among them, the products of Jilin Province West Point Pharmaceutical, Sichuan Kelun Pharmaceutical, Shandong Tokyo Medical Pharmaceutical, and Hunan Dongting Pharmaceutical have successfully passed the evaluation; 4 The company submitted the product listing application under the new registration classification, and the products created by Zhejiang Huahai Pharmaceutical, Fuan Pharmaceutical, Ningbo Tianheng Pharmaceutical/Fujian Haixi New Drug have been approved for production and deemed to have been reviewed.
From 2021 to the present, Dongyang Pharmaceutical has been approved for marketing
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, since 2021, Dongyang Pharmaceutical has been approved for marketing of 4 generic drugs, among which Entacapone tablets are the first imitation, and duloxetine hydrochloride enteric-coated capsules are the company’s first antidepressant imitations approved for marketing.
Pharmaceutical.
com, since 2021, Dongyang Pharmaceutical has been approved for marketing of 4 generic drugs, among which Entacapone tablets are the first imitation, and duloxetine hydrochloride enteric-coated capsules are the company’s first antidepressant imitations approved for marketing.
Pharmaceutical.
New antidepressant drug being developed by Dongyang Sun Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of new antidepressant drugs, the domestic class 1 new drug HEC113995PA·H2O tablets are in phase I clinical trials, and the 2.
2 class improved new drug vilazodone hydrochloride tablets have been applied for clinical trials and are currently under review and approval.
2 class improved new drug vilazodone hydrochloride tablets have been applied for clinical trials and are currently under review and approval.
Source: Minet database
Note: The statistics are as of March 25.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Medical News, March 26.
Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for listing.
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 2 billion yuan.
Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for listing.
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2019 exceeded 2 billion yuan.
Escitalopram is the single-S-enantiomer of citalopram, a bicyclic hydrogenated phthalide derivative, and is clinically used to treat depression, panic disorder with or without agoraphobia.
According to data from Meinenet, the total sales of escitalopram oxalate tablets in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 exceeded 20 100 million yuan, the growth rate has declined in the first half of 2020.
Hospital hospital hospital pharmacy pharmacy pharmacy Consistency evaluation and application status of escitalopram oxalate tablets (including new classification for production)
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, 5 companies have submitted supplementary applications for the consistency evaluation of escitalopram oxalate tablets.
Among them, the products of Jilin Province West Point Pharmaceutical, Sichuan Kelun Pharmaceutical, Shandong Tokyo Medical Pharmaceutical, and Hunan Dongting Pharmaceutical have successfully passed the evaluation; 4 The company submitted the product listing application under the new registration classification, and the products created by Zhejiang Huahai Pharmaceutical, Fuan Pharmaceutical, Ningbo Tianheng Pharmaceutical/Fujian Haixi New Drug have been approved for production and deemed to have been reviewed.
Enterprise business enterpriseAmong them, the products of Jilin Province West Point Pharmaceutical, Sichuan Kelun Pharmaceutical, Shandong Tokyo Medical Pharmaceutical, and Hunan Dongting Pharmaceutical have successfully passed the evaluation; 4 The company submitted the product listing application under the new registration classification, and the products created by Zhejiang Huahai Pharmaceutical, Fuan Pharmaceutical, Ningbo Tianheng Pharmaceutical/Fujian Haixi New Drug have been approved for production and deemed to have been reviewed.
From 2021 to the present, Dongyang Pharmaceutical has been approved for marketing
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, since 2021, Dongyang Pharmaceutical has been approved for marketing of 4 generic drugs, among which Entacapone tablets are the first imitation, and duloxetine hydrochloride enteric-coated capsules are the company’s first antidepressant imitations approved for marketing.
Pharmaceutical.
com, since 2021, Dongyang Pharmaceutical has been approved for marketing of 4 generic drugs, among which Entacapone tablets are the first imitation, and duloxetine hydrochloride enteric-coated capsules are the company’s first antidepressant imitations approved for marketing.
Pharmaceutical.
New antidepressant drug being developed by Dongyang Sun Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of new antidepressant drugs, the domestic class 1 new drug HEC113995PA·H2O tablets are in phase I clinical trials, and the 2.
2 class improved new drug vilazodone hydrochloride tablets have been applied for clinical trials and are currently under review and approval.
2 class improved new drug vilazodone hydrochloride tablets have been applied for clinical trials and are currently under review and approval.
Source: Minet database
Note: The statistics are as of March 25.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
